st-400
Generic: Autologous CD34-positive BCL11A-disrupted Hematopoietic Progenitor Cells ST-400·Code: ST-400
st-400: developed by 1 company. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Bioverativ Inc. (BIVV) | Phase 1/Phase 2 |
Get deeper analysis on st-400
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis